US Food and Drug Administration (FDA) has given a final nod to Zydus Cadila for marketing the anti-hypertension drug in the strengths of 4mg, 8mg, 16mg and 32mg. The final approval from the US health regulator to market the drugs named candesartan cilexetil tablets that are used for the treatment of hypertension.
Zydus Cadila has said in BSE filing today that the company has got approval to market the drug different strengths 4mg, 8mg, 16mg and 32 mg. This drug will be manufactured at its formulations manufacturing facility in Moraiya, Ahmedabad.
More than 140 approvals are recorded to its credit and have so far filed over 300 abbreviated new drug applications (ANDAs) since it started filings in the year 2003-2004. Following the development and increase in the approvals, the stock advanced 4.62 per cent to Rs. 483.85 on BSE. The stock opened at Rs. 465.85 and touched an intraday high and low of Rs 484.60 and Rs. 465.75 respectively in the first hour of trade.
For the quarter ended June 30, 2017, Zydus Cadila reported a total revenue at 1,055.40 crores and its net profit stood at 91.40 crores.